(Corrects cash reserve figure to $69.1 mln, not $69,122)
May 25 (Reuters) - Australian regenerative medicine maker Mesoblast Ltd MSB.AX said on Thursday it needed new funding from a third party partner or from capital raising to continue in business as it had cash reserves of $69.1 million.
"There is a material uncertainty that may cast significant doubt on the group's ability to continue as a going concern," it said in a filing to the U.S. Stock Exchange.
Shares in Mesoblast were down 4.8 percent in late afternoon trade.